WHO approval for India's COVID-19 vaccine Covaxin is further delayed over some technical queries.

WHO has requested more technical details from the Indian company before it can approve the vaccine.

WHO has requested more technical details from the Indian company before it can approve the vaccine.India has been administering its population with two of its homegrown COVID-19 vaccines - Covishield manufactured by SII and Covaxin by Bharath Biotech. Along with this Russia's Sputnik V vaccine is also available in India in small quantities. Covishield has already been approved by WHO and the other vaccine is in the process of getting listed under the emergency use authorization (EUA). Covaxin has demonstrated an efficacy rate of 77.8 percent during the late-stage trials.

The expert committee of the health agency is reviewing the details submitted by the manufacturer and sought more information related to the vaccine. The move comes despite the fact the company asserting that it has submitted all data required for clearance. WHO's nod for Covaxin would facilitate easy movement of students, medical tourists, business travelers, and others.